Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2 - Scorecard - MDSpire

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

  • By

  • Selim Chaib

  • José Alberto López-Domínguez

  • Marta Lalinde-Gutiérrez

  • Neus Prats

  • Ines Marin

  • Olga Boix

  • Andrea García-Garijo

  • Kathleen Meyer

  • María Isabel Muñoz

  • Mònica Aguilera

  • Lidia Mateo

  • Camille Stephan-Otto Attolini

  • Susana Llanos

  • Sandra Pérez-Ramos

  • Marta Escorihuela

  • Fatima Al-Shahrour

  • Timothy P. Cash

  • Tamara Tchkonia

  • James L. Kirkland

  • María Abad

  • Alena Gros

  • Joaquín Arribas

  • Manuel Serrano

  • May 29, 2026

  • 0 min

Share

Clinical Scorecard: Correction: Intratumoral Senescent Cells Expressing PD-L2 Limit the Effectiveness of Chemotherapy

At a Glance

CategoryDetail
ConditionIntratumoral Senescent Cells and Chemotherapy Response
Key MechanismsExpression of PD-L2 by senescent cells
Target PopulationPatients undergoing chemotherapy
Care SettingOncology

Key Highlights

  • Correction of representative images in Fig. 1a
  • Error involved images from control and 1 μM palbociclib treatments
  • Correct images for control and 5 μM palbociclib now included
  • Additional Source Data file prepared with representative images
  • Amended figure available in HTML and PDF versions

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients with melanoma receiving chemotherapy

          Impact of PD-L2 expression on chemotherapy effectiveness

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

            • by Selim Chaib, José Alberto López-Domínguez, Marta Lalinde-Gutiérrez, Neus Prats, Ines Marin, Olga Boix, Andrea García-Garijo, Kathleen Meyer, María Isabel Muñoz, Mònica Aguilera, Lidia Mateo, Camille Stephan-Otto Attolini, Susana Llanos, Sandra Pérez-Ramos, Marta Escorihuela, Fatima Al-Shahrour, Timothy P. Cash, Tamara Tchkonia, James L. Kirkland, María Abad, Alena Gros, Joaquín Arribas, Manuel Serrano

            • May 29, 2026

            Related Content

            Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

            Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

            Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer